

Emerging Challenges In Primary Care: 2017

Activity Evaluation Summary

CME Activity: Emerging Challenges in Primary Care: 2017

Saturday, August 26, 2017 Detroit Marriot Troy Troy, MI 48084

Course Director: Gregg Sherman, MD

Date of Evaluation Summary: January 3, 2018



300 NW 70th Avenue • Plantation, Florida 33317 (954) 723-0057 Phone • (954) 723-0353 Fax email: info@naceonline.com

In August 2017, the National Association for Continuing Education (NACE) sponsored a live CME activity, Emerging Challenges in Primary Care Update 2017, in Troy, MI.

This educational activity was designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about varied conditions such as Lipid Management, Microvascular and Microvascular Outcomes into Diabetes, Integrating Diet and Lifestyle Management into Diabetes, Solving PSA Dilemma, Hypertension.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Four hundred fifty-eight healthcare practitioners registered to attend Emerging Challenges in Primary Care: 2017 in Troy, MI and four hundred eighty-three registered to participate in the live simulcast. Five hundred fifty-one healthcare practitioners actually participated in the conference: Two hundred forty-four attended the conference in Troy, MI and three hundred seven participated via the live simulcast. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Two hundred thirty completed forms were received. The data collected is displayed in this report

CME ACCREDITATION



The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7.0 contact hours of continuing education (which includes 1.75 pharmacology hours).

AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 7 Category 1 credits for completing this activity.

EMERGING CHALLENGES IN PRIMARY CARE: UPDATE 2017

August 26, 2017 Troy, MI Live & Simulcast What is your professional degree?

Label	Frequency	Percent
MD	266	48%
DO	19	3%
NP	229	40%
PA	30	5%
RN	15	3%
Other	5	1%
Total	564	100%

Indicate the number of patients you see each week in a clinical setting regarding each

therapeutic area listed: Hyperlipidemia

Label	Frequency	Percent
None	72	13%
1-5	78	14%
6-10	80	15%
11-15	66	12%
16-20	58	11%
21-25	55	10%
> 25	135	25%
Total	544	100%

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: Diabetes

Label	Frequency	Percent
None	69	13%
1-5	74	14%
6-10	76	14%
11-15	76	14%
16-20	56	10%
21-25	68	13%
> 25	117	22%
Total	536	100%

Upon completion of this activity, I can now: List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease; Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction; Discuss ACC guidelines on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease; Employ guideline-directed treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations.

Label	Frequency	Percent
Yes	440	81%
Somewhat	96	18%
Not at all	6	1%
Total	542	100%

Upon completion of this activity, I can now: Recognize the evolving epidemiology and improvements in control rates of hypertension; Review proper blood pressure (BP) measurement technique and the role of office, home, and 24-hr Ambulatory BP measurement in the diagnosis and treatment of hypertension; Recognize current recommendations for first-line agents in the treatment of hypertension; Discuss the impact of recent trials and recommendations on evolving BP treatment goals for individualized therapy.

Label	Frequency	Percent
Yes	490	89%
Somewhat	54	10%
Not at all	4	1%
Total	548	100%

Upon completion of this activity, I can now: Describe the role of the kidney in glucose metabolism in health and disease; Review the physiologic effects and clinical efficacy of SGLT-2 therapy in various patient populations; Review emerging data on possible renal and macrovascular effects of evidence-based diabetes treatment options; Integrate the impact of treatment decisions on postprandial hyperalycemia and risk of hypoglycemia.

Label	Frequency	Percent
Yes	428	78%
Somewhat	119	22%
Not at all	2	0%
Total	549	100%

Upon completion of this activity, I can now: Understand ways to integrate lifestyle management into diabetes care; Discuss strategies to help patients improve dietary management of their diabetes; Recognize how to improve medication adherence for patients at various stages of diabetes.

Label	Frequency	Percent
Yes	479	90%
Somewhat	53	10%
Not at all	2	0%
Total	534	100%

Upon completion of this activity, I can now: Recognize the different viewpoints surrounding the use of PSA for prostate cancer screening; Discuss the evolving guidelines for prostate cancer screening; Understand the repercussions of both screening and not screening; Develop a logical approach to screening for prostate cancer in a primary care setting.

Label	Frequency	Percent
Yes	422	82%
Somewhat	86	17%
Not at all	6	1%
Total	514	100%

Upon completion of this activity, I can now: Define Patient Experience & How to Measure it; Describe today's Healthcare World; Outline the importance of the Patient Experience; Understand & apply the H.E.L.P. communication method.

Label	Frequency	Percent
Yes	416	85%
Somewhat	70	14%
Not at all	5	1%
Total	491	100%

Overall, this was an excellent CME activity:

Label	Frequency	Percent
Strongly Agree	427	76%
Agree	130	23%
Neutral	3	1%
Disagree	0	0%
Strongly Disagree	1	0%
Total	561	100%

Overall, this activity was effective in improving my knowledge in the content areas presented:

31000116041		
Label	Frequency	Percent
Strongly Agree	419	75%
Agree	139	25%
Neutral	3	1%
Disagree	0	0%
Strongly Disagree	0	0%
Total	561	100%

As a result of this activity, I have learned new and useful strategies for patient care:

Label	Frequency	Percent
Strongly Agree	395	71%
Agree	151	27%
Neutral	12	2%
Disagree	0	0%
Strongly Disagree	1	0%
Total	559	100%

How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent
Very Likely	397	71%
Somewhat likely	99	18%
Unlikely	6	1%
Not applicable	53	10%
Total	555	100%

When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent
Within 1 month	335	61%
1-3 months	122	22%
4-6 months	11	2%
Not applicable	80	15%
Total	548	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker: Jan Basile. MD - Lipid Management

Label	Frequency	Percent
Excellent	431	81%
Very Good	90	17%
Good	9	2%
Fair	0	0%
Unsatisfactory	0	0%
Total	530	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker: Jan

Basile, MD - Hypertension

Label	Frequency	Percent
Excellent	434	81%
Very Good	94	18%
Good	6	1%
Fair	0	0%
Unsatisfactory	0	0%
Total	534	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Mark Stolar, MD - Diabetes and Vascular Disease

Label	Frequency	Percent
Excellent		75%
Very Good		21%
Good		4%
Fair		1%
Unsatisfactory		0%
Total		100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Mark Stolar, MD - Diabetes - Diet and Lifestyle

Label	Frequency	Percent
Excellent	408	76%
Very Good	113	21%
Good	12	2%
Fair	1	0%
Unsatisfactory	0	0%
Total	534	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Matt Rosenberg, MD - Prostate Cancer

Label	Frequency	Percent
Excellent	403	81%
Very Good	85	17%
Good	8	2%
Fair	1	0%
Unsatisfactory	1	0%
Total	498	100%

In terms of delivery of the presentation, please rate the effectiveness of the speaker:

Marlene R. Wolf, MD, FAAFP - Patient Experience

Label	Frequency	Percent
Excellent	358	76%
Very Good	95	20%
Good	14	3%
Fair	3	1%
Unsatisfactory	0	0%
Total	470	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Jan Basile, MD - Lipid Management

Label	Frequency	Percent
Excellent	433	82%
Very Good	82	16%
Good	10	2%
Fair	0	0%
Unsatisfactory	0	0%
Total	525	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Jan Basile. MD - Hypertension

Label	Frequency	Percent
Excellent	445	84%
Very Good	78	15%
Good	6	1%
Fair	0	0%
Unsatisfactory	0	0%
Total	529	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Mark Stolar, MD - Diabetes and Vascular Disease

Label	Frequency	Percent
Excellent	432	80%
Very Good	98	18%
Good	8	1%
Fair	1	0%
Unsatisfactory	0	0%
Total	530	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Mark Stolar, MD - Diabetes - Diet and Lifestyle

Label	Frequency	Percent
Excellent	438	83%
Very Good	85	16%
Good	7	1%
Fair	0	0%
Unsatisfactory	0	0%
Total	530	100%

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Matt Rosenberg, MD - Prostate Cancer

<u> </u>				
Label	Frequency	Percent		
Excellent	416	82%		
Very Good	86	17%		
Good	6	1%		
Fair	0	0%		
Unsatisfactory	1	0%		
Total	509	100%		

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Marlene R. Wolf, MD, FAAFP - Patient Experience

in the state of th		
Label	Frequency	Percent
Excellent	391	81%
Very Good	85	18%
Good	7	1%
Fair	1	0%
Unsatisfactory	0	0%
Total	484	100%

Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent
Topics covered	440	32%
Location/ease of access	368	27%
Faculty	128	8%
Earn CME credits	452	33%
Total	1388	100%

Future CME activities concerning this subject matter are necessary:

Label	Frequency	Percent
Strongly agree	330	60%
Agree	201	37%
Neutral	15	3%
Disagree	2	0%
Strongly Disagree	2	0%
Total	550	100%

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment

Improve treatment by statin to reduce cardiovascular risk

Recognize current recommendations for first-line agents in the treatment of hypertension Discuss strategies to help patients improve dietary management of their diabetes

Managing pts who do not initially tolerate statin therapy

ensuring that proper BP techniques are utilized by ancillary staff

Better understanding of when/why to use PSA/DRE

reinforcement of educating patients on the MOA/purpose of their medications (for BP, DM, HLD, etc)

Utilizing latest epidemiology results for tailoring my treatments for my pts.

Use research/ evidences as my guideline for treatments as well

Appropriate assessment of dyslipidemia- practical guideline to use PSK9 agents - use of SGLT-2 inhibitors based on the eGFR

Discontinue sulfonylurea agents for patients experiencing hypoglycemia and not at HbA1c target

Order PSA biomarkers for male patients with 1.5 to assess prostate ca risk level such use of first-line antihypertensive agents - no Beta-blockers

Avoid using niacin with statins

Not Rx clonidine prn

Better BP collection technique

Improve bedside manners

Use HELP as guideline on how I see patients form now on

Improve overall practice with the information learned today

When to add a PSK9 for patients who are not at goal after the maximum tolerated cholesterol lowering agents

Appropriate use of SGLT-2 inhibitor

not using a Beta blocker as first line antihypertensive drug

using PSA biomarkers with healthy male patients whose PSA screening is 1.5

-use of HELP communication method always

Proper blood pressure measurements

Aanti-PCSK9 monoclonal antibody therapy in reducing LDL to achieve cardiovascular risk reduction

SGLT-2 therapy to manage diabetes managment

Prostate cancer screening

How to increase patient outcome by use of H.E.L.P communication method.

For Clinical ASCVD, consider adding a PCSK9 inhibitor if the goals of therapy have not been achieved after using ezetemibe.

Don't use a beta blocker (Atenolol) in uncomplicated HTN.

Remember that when PSA is above 1.5 ng/ml further testing and evaluation needs to occur.

Have patients bring in their medication bottles to make sure they are taking their doses correctly.

Effective communication skills are crucial for patient satisfaction.and clinical outcomes.

Implementing Statin therapy

BP control therapy and monitoring

Kidney function in diabetes

Understanding value of biomarkers in elevated PSA

Understanding and apply HELP

Being cognizant of potential issues when treating diabetes such as medication costs, cultural perceptions, and managing hypoglycemia.

Targeting a lower TSA value

Assessment and approach to blood glucose control

Assessment and approach to the control of BP

Importance of ever evolving patient-clinician relationship and strategies to communicate effectively

To calculate ascvd risk more often in practice

To treat more risk patients for hyperlipidemia

To accommodate htn guidelines in practice

To use more frequent the biomarker in high psa level

Use more frequent the sglt medication in practice

2x/week online review (new) data to keep current

Better meds option

Better result

Better health for the patients

Emphaize lifestyle changes and carb counting with diabetic management.

Use new approaches to PSA screening.

Use HELP as a means to effectively communicate with patients.

Employ guideline-directed treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations.

First-line agents in the treatment of hypertension

SGLT-2 therapy

Help patients improve dietary management of their diabetes and improve medication adherence for patients at various stages of diabetes.

Logical approach to screening for prostate cancer in a primary care setting.

Communication strategies

For DM make sure to minimize hypoglycemic episodes individualize A1C targets keep weight under control consider the sgl2 earlier

For Dyslipidemia access ascvd risk don't use niacin or vibrates

HTN mgmt dual therapy is best don't use beta blockers if retention chlorlidadone may be better choice than Hctz

How to take the BP

Vital signs room should be in front of the office to avoid White coat problem

Hypertension management:

Never prescribe a beta blocker for initial therapy in uncomplicated hypertension.

Utilization of antii-PCSK9 monoclonal antibody inhibitor in conjunction with statins Avoid SGLT-2 therapy if patient is dehydrated

Proper management of hyperlipidemia with statins and anti-PCSK9 monoclonal antibody therapy.

Using SGLT-2 I in DM management

Reduction of Idl-c and role of pcsk9

Appropriate and effective use of 1st line tx of htn

Using sglt-2 tx in various population with hx/o dm

Understanding implications of polypharmacy, DM with cardiovascular risk.

Implications of treatment options in DM/CV potential risk and longterm effects.

Further understanding of hypoglycemia along with postprandial effects and discussing options with patients.

Able to now use SGLT-2 in people with renal insufficiency; use non statins in the appropriate patients; explain better dietary approaches to diabetic patients

Able to stratify patients who needed further ffup and work up or referral to rule out prostrate cancer

ACC guidline.

Use of 24 hour Ambulatory BP measurement.

Dietary management of diabeties.

PSA and guideline of prostate cancer screening.

Communication with our patients

Adding medications in a manner as which a specialist would.

Discussion of diabetes differently than before.

Adding new medication

Adding SGLT2 to medical regimen. Adding anti PCSK9 to medical management. Better BP control

Adding to statin therapy; help adherence to lifestyle changes for dm; htn assessment and taking bp measurements; use of medications for dm control; discuss psa values; improve patient experience

Addition of spironalactone to other thiazide diuretics. Change in vocabulary (eg. use the term physical activity in place of exercise)

Additional screening for PSA levels above 1.5.

HELP technique to improve patient experience at each office visit, more open ended questions, when starting monotherapy for HTN will incorporate Chlorthalidone because of its longer half-life

Although I am in Orthopedics, as I review charts for pre-operative consideration, I do come across abnormal lab values and can comment or suspect the PCP to address the abnormalities or encourage the patient to ask his/her PCP about other treatment options

always individualize each pts treatment to help them to be more compliant

Always modify doing Rx based on presence of hypoglycemia. Use NPH and regular insurance if patients cannot afford basal insulin

Am retired from active practice

Apply 2017 measures for use of statin tx

continue to use current recommendations for tx of HTN

Apply some guidelines stated above

Apply the help communication method

Apply them to my everyday practice?

Educate patients on the importance staying,?healthy diet and exercise.

Appropriate use of CCB in HTN

As Illustrated on the presentation

As lectured

As mentioned before in evaluation. Can take information learned into patient care and hopefully improve the outcomes based on info learned

Assess for OSA, COPD management; Sleep Assessment; Improved abilities to assess dementia

Assessment techniques.

Avoid use of betablocker as first line treatment for hypertension.

Be a skin doctor!

Be a good communicator

Allot paperwork to the ancillary staff

Be more mindful in analyzing PSA reports and recommendations for treatment.

Behavior medicine

benefits of chorthalidone over HCTZ

higher risk hypoglycemia in DM with CRF requires more intensive monitoring benefits of increased activity in DM doesn't need to be in chunks but can be in small segments

Better able to make decisions on management of prostate cancer screening Improve on communication skills and on Diabetes education

Better approach to management of hypertension and diabetes / Great lecture on prostatic cancer management

Better articulate consequences and risk factors for OSA, improved treatment options for migraines and it's commonality. New recommendations to treat HTN.

Better b/p management and better glycolic control

Better BP management using proper BP measurements

Better communication

Better communication methods with patients

Better deal with patients and other doctors. As in osteopath and its principles can better be integrated in my patients, other doctors

Better diabetes management, including nutrition and medication therapy

Knowing when to order biomarkers with psa level

Better communication with patients

Better evaluation and management of hypertension. Appropriate use of SGLT-2 in DM management,

Better implement guidelines with patients

Continue education with or DM patients

Use of additional dietary instructions including the use of dietitian

Better knowledge & comfort in areas covered

Better lipid management. Better BP management. Need few PSA screening. DM treatment options

Better management of HTN and correct Rx to use (updated guidelines). How to partner with patients to better manage diabetes. Improved knowledge for PSA screening/management

Better prostate cancer screening

provided better DM education to patients

more confidence prescribing SGLT2 medications

Better screening

Better tx

Better f.u.

Better treatment for dyslipidemia, htn and dmt2. Better evaluation, diagnosis and treatment/referral of prostate ca including increased risk potential.

Better understanding how to treat with statin intolerance

Better understanding of all the topics

Better understanding of the changing knowledge base in these areas= better patient care and outcomes

Better understanding of the topics presented.

Better understanding of utilizing PSA levels and when they should be used

I also have a better understanding of lifestyle modifications to teach patients regarding their diabetes

Better use of PSA screening & referrals

Better communication with patients

Better use of on-line media and ratings

Better ways of treatments and evaluation for each individual patients

BP monitoring. Use of biomarkers

BP monitoring/SGLT2 inhibitor benefits. Dyslipidemia management after failing statin

Build up treatment with Metformin. Try different statins in patients with statin sensitivity.

Reduce tight bp, blood sugar and lipid control in patients under 75 years old

can utilize what I learned in my practice

Change BP treatment, great advice on not using Beta blockers first. Thanks

Change my scope of testing for PSA and biomarkers

Improved Cholesterol management and avoid adding fenofibrates or niacin

Occillometric BP's and multiple BP measurements

Changes to lipid management

Check blood pressure 2-3 times during an office visit. D/w DM regarding physical activity, food choices, weight loss goals. Check PSA for male patients over 45, further evaluate for PSA over 1.5

Choices of HTN meds.

More comfort in prescribing SGLT-2 meds.

Improving statin therapy in my practice.

Communicating better with the patient and family.

cholesterol management and diabetes care

Choosing agents for HLD and HTN in a stepwise manner especially will be helpful.

CMS criteria for use of PCSK9 inhibitors. Non-statin medications. BP monitoring and newer guidelines

Combining PSA screen in appropriate patients with biomarker studies.

Carefully watching voice tone and body language in interviewing patients while sitting.

communication and routine follow-up for effective chronic disease management

Communication methods noted in the H.E.L.P lecture

Communication, shared decisions, compliance

Complete patient experience. Revealing the art of medicine in addition to the science of medicine. The importance of good communication, manage online reputation

Consider renal contribution to diabetes, and consider proper combination of medications for individuals.

continue treatmant

Coordinated care among practitioners for lifestyle changes and patient education

Correct BP assessment

Correct bp measurement technique, use of Spironolactone, lifestyle teaching methods, statin intolerance methods

Corroborating the evidence for best practice and considering the outliers

Current environment algorithms unable to deviate to a certain degree

Current recommendations on 1st line hypertension treatment and guidelines, clinical efficacy of sglt2, application of HELP communication method, evolving screening guidelines of prostate cancer.

Currently not seeing any patients.

Decision making

improve discussion

Decrease KO visit sessions. PCSK9 inhibitors - instead of lipid/Fibrofin to statin. SGLT-2 - monitor renal function

Define Patient Experience & How to Measure it; Describe today's Healthcare World; Outline the importance of the Patient Experience; Understand & apply the H.E.L.P. communication method.

Develop lifestyle changes plan with patient. Consider blood pressure monitoring at home and use home readings to determine treatment

Diabetes and Vascular Disease and Prostate Cancer this activity was effective in improving my knowledge in the content areas presented.

Diabetes management review

diagnostic measures according to s2017 guidelines; deep insight to DM tx (risks and benefits) and slides to use as reference (and to educate employee providers); updated EBP re: prostate

Dietary management strategies of DM type 2. Monitoring BP at home. Prostate cancer screening

Discontinue sulfanyureas in diabetics with hypoglycemia

Discuss with patient the risk factors and relevance of obtaining PSA in their condition. Apply the rationale for using an anti-PCSK9 monoclonal antibody in certain hyperlipidemia patients

DM management,

Lipid Management

Managing the patient experience

Prostate Management

Diet & Lifestyle DM patient management

Hypertension management

DM screening and management

PRostate ca screening

HTN guidelines and treatments

Dm, HTN

DM, PSA, HLD managment

do more home BP monitoring

Do more shared decision -making in ordering PSA tests and emphasize more lifestyle

Emerging Challenges in Primare Care 2017

August 26, 2017- Troy, MI.

changes that patients can do in order to control their diabetes and not just relying on meds.

Do not use Clonidine PRN. Beta blockers as first line in BP management

Don't tell patients to exercise, encourage "physical activities", they say they enjoy/will do. Teach what carbs are, how to meal plan, stress that orange juice/juices are carbohydrates

Don't treat - just diagnose

Early diagnosis

Primary prevention

Secondary preventive methods

Tertiary prevention

Early initiation of GLP-1 and Insulin use. Use of triple in patients with active COPD. Earlier screening for sleep OSA. Addressing differences in Dementia and treating secondary symptoms. Selecting appropriate sleep aids in the elderly.

early recognition of hypertension, importance of psa

patient approach

lifestyle changes in dm

Early starting of insulin

Educate

Educating my patients on disease process and updated clinical guidelines for treating diabetes, screening approaches for prostate cancer, lifestyle changes and other preventive measures.

Effective listening

Effective BP monitoring

Effective management of hypertension.

Proper use of blood pressure readings regarding the diagnosis of hypertension.

The effectiveness of PSAcscreening

Electronic medical records

Emerging information, good discusdion

Emphasize LDL reduction and consider use of PCSK9 if appropriate. Implement immediately new guidelines on BP control; implement new strategies in microvascular and macrovascular complication sin DM - emphasize techniques for DM diet, exercise, weight reduction.

Importance of patient experience

Employ evidence based treatment for primary and secondary prevention and recognize current recommendations.

Employ stepwise therapy for patients who may need PCSK9 therapy; statin to maximum tolerance and Zeta, continue to monitor lipids. For HTN, use these first: TZD (or TZD-like meds), ACEI or ARB, CCB. For DM: consider SGLT2 inhibitors if no PVD

Employ the knowledge learned from the program in the treatment of patients with HTN, DM, and with Dyslipidemia

Encourage all hypertensive patients to do home blood pressure monitoring; make sure HBA1C values done or are available at office visit; Consider biomarkers in men w/PSA >/= 1.5.

Encourage new clinicians to the practice to utilize our guidelines tabs on the EMR that list recommendations and criteria for application to clinical situations/presentation

Encourage patients to "create health" at every visit.

Know that obesity is a predictor for diabetes and a marker of insulin resistance.

Advise patients to exercise 30-45 minutes daily and strive for 5 % weight loss.

Reduce intake of processed foods, sugary drinks and alcohol.

Encouraging patients to participate in the decision making process, and explaining things to them.

Establishing good rapport with patients and family members through effective communication and teaching.

Evaluate PSA - initial screening score. Monitoring of blood pressure at home - encourage. HCTZ has half life of 12 hours/better alternative chlorthiadone. SGLT can be used with renal impairment (most). Encourage "physical activity" and "sustainable diet changes"

Excellent presentations.. Hope, will get more presentations in the future.

Explain reason for meds. Explain how to approach exercise. Explain exercise options. Food choice = diet

Explain the patient about disease and application of test needs

First line agents for HTN

Follow guidelines

Improving the use of PSA for prostate cancer screening

Follow practical advice on properly taking blood pressure. Follow new guidelines regarding clinically acceptable BP readings. Improve communication for better patient experience

Following the recommended guidelines presented in each of the areas listed above.

For HTN put patients on thiazides first line or begin with an ARB or ACE.

For monitoring PSA if 1.5 or lower do nothing. If above order bio specific markers. Use SGL2 inhibitors if GFr greater than 60 for type 2 diabetes.

Generally

Getting A1C's prior to visits. Knowing who and when to initiate statins and when to go to Zetia or add PCK9 agents. Avoid the word exercise. No floor to how low the LDL can go. Screen for PSA if will work it up irrespective of age.

Getting pt compliance

Good management guidelines for DM & hyperlipidemia

Good patient experience with each office visit

Good webinar

greater comfort in using the GLP 1 and 2 medicines

greatly advanced my knowledge of current medications in treatment of hyperlipidemia and diabetes melitus

Have a better understanding

Have patients bring their medication bottles

Have to think about

HCV monitoring and treatment

He needs to become aware that his voice goes down in volume at the end of each sentence and gets inaudible!

Helping to my patient with diagnosis and treatment

HIV/AIDS

Hold statin while evaluating muscle pain. Thiazides have the shortest half lives so consider using BID.

Lose 5-10% of body weight to improve insulin sensitivity. (1)

How to adjust diabetic medications for patient and how to remove and add medications. (1)

How to educate client life style modification

Manage hyperlipidemia

To safely manage blood pressure

How to improve glycemic control and monitor HgA1C more frequently to improve outcome. Blood pressure ensure to start with lifestyle modifications first and 1st choice of therapy should be diuretics

How to manage DM

Management of COPD

PS screening

How to manage PSA higher than 2.5.

How to manage and not accept hypoglyemia.

What meds to add to a station to decrease incidence of side effects.

how to take blood pressures in the office setting accurately

how to use statins correctly with other meds.

Guideline for proper use of antihypertensive.managing and helping our patients with DM better.

Know that PSA is not perfect and we need biomarkers to help for better decision making and referral.

How important it is communication with patients not only from providers, also for all the staff.

HTN management goal

Lower floor of LDL has not been established

PSA - still cloudy but see the light!

HELP pt experience

HTN management. Dyslipidemia treatment - statins. Lifestyle modification (1)

HTN Strategies and Med Management, Improved DM Management, PSA Strategies and prostate cancer

Hypertension, Diabetes, and hyperlipidemia treatment options in poorly controlled patients Hypertention algorithm.use of CHADs score. New pharmacology and use of lipids and diabetes drugs.

I am a pediatrician with a subspecialty in adolescent medicine, and I mostly treat children, teens, and adults for ADHD. While much of this information was not familiar to me, it will enhance my ability to communicate with my patients who have their primary care done elsewhere.

I don't use these stratagies as I am in occupational health

I got better understanding of mechanism of action of PCSK9 ,Better management of DM,better utilazation of BP medicines

I have learned additional measures to treat HLD and when it is prudent or not prudent to do so. Changing educational verbage in patient centered dialogue. I have a better understanding of SGLT2's and when to prescribe them

I have learned how to better diagnose and treat my patients. I have learned additional signs and symptoms to look for in specific diseases

I have learned ways to manage DM patients and their medication management Sleep and management

Demetia and different types and these are the patients I see on a daily basis and it was very helpful to understand the different types of dementia

I intend to do update and keep abreast of the changing EVB guidelines so I can be more current and competent in treating my patients.

I learned of the current thinking about the use of the PSA test and how to use it, about the most recent diagnostic tests and the latest treatments for the problems discussed.

I now understand & know when to utilize the PCSK-9 inhibitors.

I also feel more comfortable on treatment plan with use of chlorthalidone & or aldactizide in tx of B/P

The use & SGLT-2 inb is now much clearer.

The ordering of PSA & it's interpretation is also much clearer.

I was especially enlightened about PSAs, I can better guide my patients. I was scared to recommend doing a PSA, if they said they didn't want a bx- then what was the point. But doing the test, then the bombarders if the fall into that 23%, further targets a biopsy. I think patients would be more amenable to a biopsy if they were further stratified into a high risk group.

I will be obtaining a biomarker for psa of 1.5 or greater weight and diabetes and treatment guideline and statin therapies

I will be referring patients

I will change how I manage hyperlipidemia and HTN.

I will consider using SGLT 2 medications when treating DM

I will integrate lifestyle changes when treating DM

I will consider biomarkers for all PSA levels over 1.5

I will stop using Beta blockers as first line treatment for uncomplicated hypertension. I will consider adding Zetia and PCSK9 inhibitors in appropriate patients with hyperlipidemia. I will try to stop using the term "exercise" and use "physical activity" instead with my diabetic patients

I work in Emergency Medicine so a lot of what I've learned today is not applicable. If I were to switch I would adopt medication strategies learned today such as statin and ezetimibe and PCSK9. Also, diabetic medication strategies learned today would be very useful

I work in surgery, but helps keep me updated on strategies that other physicians may use and uodated on medications.

I would use the updated info to give comprehensive and safe medical and personal care in general

Improve quality of care with sensitive communication

Revise the use of different parameters for prostate cancer screening

Utilize more patient Diabetes education

Identify patients whether treatment is appropriate according to guidelines

Im retired

Makes me a better physician

implement in strategy

Implement strategies I learned from this CME

implementing better management for T2DM, Hypertension and Hyperlipidemia

Implementing better treatment plan

Communicating with patient differently regarding disease state

Education

Implementing nonstatin therapy for cardiovascular management.

Monitoring kidney function closer with diabetic management especially with GFR under 50.

Importance of statins. Importance of HTN, BP measure

Improve bedside manners

use HELP to better communicate with my patient's

use the information learned today to improve patient care (1)

Improve compliance with meds and lifestyle modifications for DM, Hyperlipidemia, and HTN. Use the HELP communication method.

Improve practice

Improve the way blood pressure is measured in the office based on guidelines. Better recommendation of first line blood pressure meds. Helping patients design and follow a healthier diet. Recommend PSA when adequate (1)

Improve use of nonstatin treatments of cholesterol. Update knowledge of newer diabetic medication. Change approach to PSA testing

Improved assessment and treatment skills

Improved dm with the use of appropriate drugs.

Use of appropriate medications to treat insomnia in elderly.

Recognize different dementias.

Suspect sleep apnea.

Improve copd treatment according to gold classification.

Improved dx and rx

improved knowledge of pharmaceutical treatments based on current, evidenced based data improved knowledge of diabetes care and management

bedside communication with patients and family

Improved lipid management knowledge

In my advanced age patient base, I will certainly look to discuss more lifestyle changes for both diabetes/HLD/HTN management, as many of my patients are reluctant to start new medications for cost/personal reasons.

Include a sleep survey in patients office visits.

Review patients history including family history for possible causes of patients problems. ie diabetes, breathing problems, and memory loss. I will increase screenings for sleep apnea. Also investigate cost of spirometry

Include spirometry with chronic respiratory assessment

Incorporate current guidelines and medications into practice to better control chronic diseases.

Increase activity ie. walking, swimming, stationary bike

Increase awareness of the 4 groups of drugs effective in treating HTN. Use of PSA level with biomarkers as a better way of screening prostate cancer

Increase my knowledge about research trends in hyperlipidemia and hypertension

indications of PSK9 in management of resistent lipidemias.

use of omega3 in hypertriglyceridemia

use of chlorthalidoneas firstline or with Ace as firstline in HTN

use of PPBS in SGLT2 for T2DM management

inform/review patient medications

Information provided can be shared with pt through verbal and visual information exchange (handouts)

Informative in positive manner. Learned better need for communication skills to help the patient

integrate lifestyle management into diabetes care; Discuss strategies to help patients improve dietary management of their diabetes; Recognize how to improve medication adherence for patients at various stages of diabetes.

Integrating lifestyle management into diabetes care. Use of proper blood pressure device Integrating new therapies based on current recommendations.

Integrating the new options, new agents and expanding lipid managements. Integrating new

treatments and managements in hypertension and diabetes. Recognizing the use of PSA for cancer screening and importance of patient's experience

Interactive session. Break provided

intergrating lifestyle management and especially diet and exircese in managing diabetes and hypertension

Involve the patient more in decision making. Increase self-management

It is very important lifestyle changes than medication, spend time to explain how effective lifestyle changes, also take wise patients language, not medical terms

Know better when to order tests to r/o prostate CA.

Know when to add or not add meds to statins

Direct pt on lifestyle changes to decrease carbs

Understand value added to pt satisfaction, communication

Understand SGLT mechanism and when to try them

Learned new methods of using SGLT-2 to lower cardiovascular risk in patients

Learned that PSCK9 meds lower LDL by 59%. Learned about SGLT2 meds

Learned the most UTD way to treat patients with hyperlipidemia resistant to statins alone.

Learning how to work around barriers such as education and cost to treat the patient with the best medications possible.

Lifestyle and lipid management

lifestyle magment

Lipid control depending on the associated risk factors. Treatment for resistant HTN. Stress on diet/lifestyle management in DM

Lipid management

PSA testing

Lipid management

Lipid management with multiple agents

Antihypertensive agent utilization with respect to comorbid conditions.

Lipid management, hypertension care, diabetes care, spa follow up.

Lipid, hypertension and diabetes management.

Listen to patients more.

Implement new knowledge.

Educate patients.

Listening

Open ended questions

Non judgemental

Look for new guidelines coming in Nov 11, 2017

Look into prescribing more of my patients SGLT 2 therapy.

Lower statin dose, alternate days to reduce side effects. PSA biomarkers. When to refer

Make necessary changes in practice

Manage DM2 more effectively. Manage hypertension better

Measure blood pressure in office without clinician physically in the room

Med management

Medication management and patient care

Medication, bp management

Meds for diabetes

Open ended questions

Meds recs for impletmenting to control BP's

Taking Pts BP's in office setting and comparing pts home readings to determine adherence to meds; making sure when BP's at taken that legs not crossed and arm is heart level Using the term Physical Activity vs using the term exercise when discussing wt loss with pts

Modify and correct the manner in which blood pressure is measured in the office. Pursue having patients measure blood pressure at home. Use these insurance BP. Do medication reconciliation with patients. Using terms "physical activity" instead of "exercise" and "diet" when educating diabetic patients

Monitor more aggressively lipid levels

Monitoring for hypoglycemia and medication changes

More acurrate aglorithm

More aggressive and earlier treatment of problem

More aggressive Rx of HTN, referering patients early to urologist with PSA 2-3 range

More educating patient

More focused selection of available agents for treatment of T2DM

More knowledge regarding diabetic management and lipid management

more knowledgeable

More known options now available to me. Better screening use. Improve clinical care

More PSA screening

Improving compliance

Better DM control

more targeted use of PSA testing and broader range of possible interventions to include nonintervention

increase use of life style counseling

More useful PSA criteria.

N/A I am in occupational Medicine

Neutral

New agents in diabetes management

New Agents, New Options, and Expanded Potential In Lipid Management

New approach to PSA and much better understanding of SGLT2's

New diabetic med SGLT2 inhibitor. Studies done on various new meds and side effects

New Guidelines

New guidelines for managing HTN, diabetes, and lipids

New HTN guidelines

New HTN guidelines in diabetes

PSA surveillance using 1.5 standard

New lipid guidelines. Improved diabetes care. Excellent lecture about PSK

New lipid management with diabetes. Use biomarkers for prostate cancer

New look in guideline of treatment and evaluation

New medication. New recommendations

New medications in treating hypertension, hyperlipidemia, etc. New affects in evaluating patients with low or high risk of developing prostate carcinoma

New medications use in hypertension/diabetes

New options for HLD treatments, life style modifications

New topics that we treat

New treatment approaches

Niacin not used in combo therapy. PSA

No beta blockers for primary hypertension. Use long term Thiazde. Correct CT > 4.0

Non statin treatment for high cholesterol. Dietary advice for T2DM and what will happen otherwise. Be more aware of patient experiences. Give value and quality (1)

None

Not applicable

Not doing direct patient care

Not to use beta blocker as first medication for HTN. Do not use clovaalizine PRN B2 hygatursive. Not add niacin or femofibrate to statin as it will not improve hyperlipidemia

Obtain applicable study results

Oo

Optimized thorough discussion of PSA and options with patients.

Better more comprehensive options for lifestyle modification for diabetic patients.

Outreach

Engagement

Self-management

Self-efficacy

Patient experience

Patient satisfaction

Patient-centric coordinated care.

PCSK9 inhibitors use Ezetamide and spironolactone use, current therapies in lipid, HTN, proper monitor of PSA in men

PCSK9 treatment strategies, Consideration of new therapies in diabetes, relevance of different bp measurements and their implications.

Pertinent educational goals for explaining how to manage and prevent diabetes

Pharmacotherapy, lifestyle integrative strategies

plan on using more additional newer meds now that i understand their action better

Practical information for primary care practice

Prescribing lipid lowering agents and anti-hypertensive medications and considerations for both

Proper BP management and measurement, statin and adjustment of proper therapy. Communication, keep teaching. 1.5 to start testing and add therapy. Work a specialty so some things I can't implement

Proper history, labs

Proper management for HLD - med therapy

Proper management of hyperlipidemia based in risk factors and ASCVD calculator. BP monitoring

Proper measurement of BP

proper treatment and management of hypertension/DM

Provide patient education on disease progress and treatment plans

PSA

The importance of postprandial BS

PSA

PSA screening in men.

Understand guidelines for referrals.

Diabetes treatment & lifestyle importance, side effects.

PSA 1.5 for prostate cancer screening

PSA and when to send to urology. How to approach patient with DMII physical activity versus exercise. Diet versus food choices. Communication skill will change. Very confident in treating hyperlipidemia and HTN

PSA screen and Biomarkers as next step.

Stop sulfonylureas then add.

H.E.L.P. is another way of saying "be a good Doctor".

Check 24 hour BP to determine actual number to treat indicative of disease process.

Insurance does not always want to pay for what is correct.

Pt encounter for lifestyle modification in diabetes. Discussion of PSA testing. Selection and discussion of HTN treatment and checking pt compliance

Re-think about HCT2/Atanold. SGLT2 care

Recheck LDL-C after starting a statin response is important, spirondlactone great for African Americans

Recognize current recommendations for first-line agents in the treatment of hypertension Discuss strategies to help patients improve dietary management of their diabetes

Recognizing and diagnosing HTN, utilizing clinical guidelines appropriate monitoring of BP, having patient bring medications to the office.

DM utilizing SGLT 2's more on patient who are good candidates for meds, integrating diet and exercise in practice

Recognizing and diagnosing patients. Using evidence based practice guidelines to treat those patients

Recommend Ezetimibe after statin if LDL-C not low enough and then PCSK9 inhibitors

Refer Pt. with borderline PSA elevation to Urologist

Refresh and good to know regarding how to manage chronic dz patient.

Retired

Review lipid goals

review my BP strategies for the office.

Outline ways to improve medication adherence in management of DM.

Improve communication with patients

review pt records/ s/s

RIght treatment. Patient education

Role of Anti-PCSK9 in lipid management

Importance of patient inclusion in the decision making process as well as the importance of pt education with DM and HTN management

Utilizing the H.E.L.P communication method

Role of statin and non-statins. Use of Aldactone in therapy of HTN. Role of SGLT2. Lifestyle and diet treatments

ROMC CARD diet for diabetes

routine a1c and follow up for better management

Rx for DM - although I will not use in my practice, it is good information

Screen for Alpha 1. Use new guidelines for hypertension and hyperlipidemia treatment

Screen for prostate cancer, prescribe PCSK9 inhibitors

Screen more patients.

Screening for PSA, healthy lifestyle modifications for the diabetic patient, correct way to take blood pressure so that I can address that with our nursing staff, better understanding on how to combine therapy in hyperlipidemia management.

Screening for PSA. Treatment of HTN, DM

Screening for risk of metastatic prostate cancer in lifetime. Choosing antihypertensive agents, pros and cons within the second class. Correlating patients behavior with what their body is doing in regards to insulin to enhance patient buy-in

Screening is essential. Managing hypertension early prevents cardiac complications. Good glucose control decreases cardiac risks, micro and microvascular complications, such as loss of vision, renal comprise, myocardial infarction, and limb loss. Management of hyperlipidemia is essential to decrease vascular complications such as MI and CVA. Attention to family history and PSA screening is critical to finding cancer in the early stages and preserving quality and length of life.

screening strategy, and changing treatment approach

Screening, following up

Screening. Appropriate medications. Ancillary interventions

Send patient to urologist if the PSA is above 2.5

Aggressive lipid management

Management of diabetes complications

Better control of Hypertension

Shared decision making

Explain the mysteries of medical world

Effective communication

Active listening

Shared decisions

Some statin is better than no statin. There isn't a "too low" LDL. Say "physical activity" instead of "exercise". To reverse insulin resistance - need to lose 7% of TBW. I work in Palliative and hospice

Specifically appreciate the lecture regarding blood pressure goal setting and the information about dietary compliance for diabetic patients.

Statin benefit groups; age provides integrated estimate of lifetime exposure to risk factors; theory re PCSK9 inhibtors; preferred thiazide diuretics for HTN; benefits SGLT2 inhibitors; PSA levels; effective communication

statins and cardiovascular disease prevention

Importance of patient involvement

the importance of psa screeninb

Stepwise adjustment for lipid control

Still thinking or planning my strategies!

Strategies related to primary care involving cardiovascular risk factors

Stronger use of PCSK9. Better algorithm for BP control. Increase use of SGLT2 inhibitors

Switch to lower statin dose. SGLT2 monitor GFR. Healthy with high PSA check biomarkers

Taking the extra time to listen fully

Targeting the patient's experience is important

Thank you

Thanks

The role of effective communication.

Useful information on how to effectively deal with barriers to diabetes care for the individual patients.

CMS use of penalties to practices, and hospitals for negative patient reviews via survey.

The usage of chlorthozicine as a first line treatment in hypertension. Utilizing more SGLT-2

agents in the treatment of some of my harder to control diabetes (1)

The use of prostate biomarkers was new information to me. I will be sharing this information with colleagues. I appreciated the review of HTN treatment, particularly the current guidelines regarding 1st-line agents. If we have difficulty communicating with and connecting to patients, there is greater risk that they will not be adherent to therapy. Appreciate the reminder regarding that today. (1)

This is the wrong survey for the conference I attended. I attended the one presented in Nashville.

THIS IS WRONG EVALUATION FOR NASHVILLE WEBINAR. PLEASE SEND CORRECT EVALUATION!

Tighter BP monitoring - away from office

To help patient to improve dietary management

To help patient to be more proactive in regular exercising.

Treatment

Medication

Follow Up

Treatment and management of both hypercholesterolemia and HTN. Key steps to follow on decision making. Discuss nutrition and physical activity with all patients. Consider PSA testing at age 45. On men with levels over 1.5. Consider more testing

Treatment of CAD, hypertension, diabetes

Understanding of PSA

Treatment regimens

Try not to interrupt patients when they are talking.

Try to introduce new modalities of treatment

Uncontrolled hypertension is serious and can reduce life expectancy of about 5 years. Close follow up is necessary to emphasize taking their medicine regularly. Beta blockers should not be the first line drug to choose in hypertension

Understanding DM type 2 treatment combination and close follow up for possible side effects understanding medication indications and usage

undertand the need of lifestyle changes in the management of diabetis, hyperlipidemia of control their condition

Update in lipid management

update on guidelines and new strategies

Us ACC guide lines, Use Better blood pressure monitoring for diagnoses and treatment, better postprandial blood sugar control

Use 3 medications in first line BP control. BP measurement should be standardized at home rather than office

Use aggressive lipid and sugar controls.

PSA considerations.

use all strategies

Use effectively new agents. follow guidelines. follow macro vascular & microvascular recommendation. diet & Exercise

Use more chlorthatidone. Have patients do more carb journaling instead of food journaling. Order more biomarkers for PSA >1.5. Read all surveys

use new DM medications to get better control of DM in my pts and reduce cvd

Use of anti-PCSK9 in lipid management. Strategize to change diet and lifestyle with diabetic patient. Use of biomarkers in managing risk in patients with PSA over 1.5 mg/ml

Use of anti-PCSK9 monoclonal antibody therapy combination of statin and ezetimibe not effective in achieving LDL goal in high cardiovascular risk group. Goal HTN < 140/ 90 for Age

Use of ezetimibe, PCSK9 in patients taking statin.

Not adding niacin to a statin

Use of chlorthalidone due to its long half life vs HCTZ short half life

Not using BB as 1st line agent

PSA and utilizing biomarkers

diet and lifestyle in DM

effective communication

Use of lipid lowering agents more aggressively, better understanding of SGLT 2 drugs, better understanding of gyn and drug clssses

use of newer medication for diabetes and cholesterol control

USe of newer therapies

Use of PCSK9 inhibitor. Restriction of Beta blockers as first line in HTN

Use of proper BP monitoring

Use of SGLT 2.

Discussion of PSA screening

Improving patient experience

Use of SGLT2 for PP hyperglycemia

Use of statin therapy in prevention and treatment of cardiovascular disease. Improvement in the control of HTN

Use of statin, treatment of hypertension, treatment of PAC. Very educational

Use PCSK9

Use Psk9 for Ldl not responding to statin and zetia third line.

Use sqlt2 inhibitors to reduce posprandial glucose.

Only further screen for PSA above 1.5

Use recomended medications in better way

Use SGLT2 for diabetes management

Use biomarkers for PSA level above 1.5

Use less than BP 140/90 as goal for all ages regardless of diabetes status

Use strategies and sequence of medications in treating hyperlipidemia, diabetes, and HNT

use the resources and the lecture content

Using biogenetic market in PSA of 1.5 or greater.

Using high dose statin. Using SGLT2

Using medication and function strategy to adjust medications

Using monoclonal antibodies in controlling LDL

Strategies in controlling blood pressure

using more GLPs

Using new approaches to manage hyperlipidemia and risk assessments for patients candidate for PSA measurement and diabetic therapies

Using new DM meds

Utilize GLP-1's more often in my practice to increase B-cell activity in my diabetic patients (1) utilize the knowledge that I learned from this conference to apply in my practice, spend more time with the patient

Utilizing the PSK9 drugs in order to reach LDL goals; using different approaches and bargaining with diabetics; understanding PSA and learning about the patient experience to

serve my patients.

Utilizing the things that I have learned from this educational activity, I will be more aggressive in the treatment of the conditions discussed to have desired treatment goals

Utilizing updated guidelines and recommendations for patient management.

Variation of Medicines.

Various options for diabetic control

When to add which lipid med

When to screen and refer for elevated PSA.

Which statin and nonstatin and primary or secondary

Who would best benefit in using SGLT2 therapy,

When to refer a PSA out and when biomarkers are helpful,

Teaching carbs in a way pts understand

Will attempt better control of DM and

Dyslipidemia with newer drugs.

Will attempt better Hypertension assessment and control based on new information that was provided in the Lecture.

Will be utilizing the newer recommendations for B/P, DM management, and PSA.

Will implement in my practice with education and prescribing.

Will implement in patient care

Will try to follow ACC guideline to control hyperlipidemia and HTN better. Will attempt to be aggressive in controlling lipids by using statins and PCSK9. Will try to sit down and talk more with patients and educate them about diet and physical activities

With review medications my patients are taking and make change to align the regimen with evidence/best practice guidelines. Discontinue medications that are not effective. When using HCT2 prescribe it at twice a day instead of once

Assessment and treatment of Diabetes Mellitus

Improved assessment of Blood Pressure measurement techniques and subsequest treatment if indicated

Assessment of PSA results

How to speak more effectively to patients about needed life changes to help them improve their health.

What topics would you like to see offered as CME activities in the future?

Comment

About Dementia and Alzheimer's Disease

Adolescent medicine, Asthma

Advances in congestive heart failure and stroke and coronary artery disease medical Rx

Aging and medicine challenges. Arthritis. Cancer surveillance

Alzheimer's Disease

Anv

Arthritis/obesity/chronic pain and alternative therapies

Arthropathy - RA, OS - new Rx. Multiple Sclerosis - new Rx

Asthma versus COPD. CHF. Thyroid; GI approach

Asthma, COPD. Eczema. Irritable Bowel Syndrome. Arthritis

Atrial Fibrillation. COPD. Heart failure Autism spectrum. ADHD Autoimmune diseases CA-125. Ovarian cysts Cardiovascular disease. Renail failure. Hepatic failure Cardiovascular, Neurology Cerebrovascular disease CHF management (outpatient) Choosing antibiotic therapy (Chronic low back pain. Stroke. COPD. EHR - tips, notes too overwhelmed Community acquired pneumonia. GERD COPD management. Chronic pain management without chronic opioids. Achieving remission in chronic depression - with patients "too busy" for psychotherapy COPD. Asthma. Thyroid disorder. Lipids, AAI COPD. BRCA. Infectious Disease Cost of health care and affordability given the current state of affairs Cough. Pneumonia. HTN. DM management CVA. Asthma. Anemia CVA. Parkinson's Disease Defractory hypertension. Cases on how to implement various diabetic meds Dementia management Dementia. P.D. Depression management in elderly. Wound care. Peri-menopause women's health. Dementia/Alzheimer's early diagnosis and management Depression/anxiety, psych management in Primary Care Dermatology topics. Other careers for physicians other than clinical medicine due to the changes in medicine, more PA's and NP's doing our jobs! Diabetes and neuropathy treatments and options. Dialysis; pain, chronic - management Diabetes, diet, lifestyle, vascular diseases, prostate, HTN, lipid management, patient experience Dialysis versus transplant. Lab values. Diet and importance in renal patients Diastolic dysfunctions with and without heart failure and treatment modalities. Cardiomyopathies and treatment DM. HTN. CKD DM. Hypertension DM2 meds Drug addiction treatment protocol Endocrine organ dysfunction. Arthropathies with newer modalities of treatment. Improved patient communication Erectile dysfunction. Impotence. Lung cancer. Dementia. Diastolic CHF. Osteoporosis men/women. Opium indications abuse Fall risk assessment and prevention. Dementia. Obesity Genetic factors in diseases. Finding a solution by genetic modification

GERD. GOUT. Urinary tract infections. Cellulitis

HCV. Oncology

Headache/migraine management. Women's Health

Heart failure in Primary Care. Osteopenia/Osteoporosis. PCOS. Depression/anxiety in Primary Care. Uncomplicated Dermatology conditions in Primary Care

Heart failure, CVD

Hematology/Oncology

Hepatitis

Hepatitis B/C

Hepatitis. AFib. Vascular defects

HIV

Hormonal replacement, menopausal evidence-based treatments

Human trafficking, to know what to look for

Hypogonadism. RA management. Locum Jenens, do's and don'ts. Childhood obesity. Opioid management addiction in PC setting

ID topics - any

Identify Atrial Fib and use of anticoagulants. Use of anticoagulants concerning duration with improved clinical tests

Inclusion of some gyn subjects

Infectious Disease issues: treatment and selection of proper antibiotics for CAP, Bronchitis, etc. Asthma update. Inflammatory bowel disease update. Regulatory review. Sarcoid overview including trends, treatments, etc.

Issues facing the senior population

Latent TB. What it's all about and treatment

Limbo sacral disc disease treatment

Low back pain

Medical management of post MI patient. Medical management of diabetics (type II) on insulins. Follow up on prostate screening (especially with Dr. Rosenberg)

Menopause symptoms treated with HRT and safety

Mental health in primary care

Metabolic bone disease. Orthopedics, especially being able to distinguish between hip vs low back pain and shoulder versus cervical pain

Metabolic syndrome. Obesity, diabetes, hyperlipidemia updates. Osteoporosis. Menopause.

Falls. Degenerative arthritis. Rheumatoid arthritis

Musculoskeletal pain and management

Nephrology related topic. Thyroid related topic. Vitamin D related topic

Neuro topics or Epilepsy, Parkinson's disease, Dementia, etc.

Neuro/Psy

Neurological problems/diseases. Hematological problems/diseases. Renal diseases

Neurology, headaches, Dementia. ID-Sepsis

Neurology/psychiatry topics, also infectious diseases

New insulins, Tujeo, Tresiba, basal bolus insulin strategy, insulin pumps and CGMS

New Nov. 11, 2017 HTN guidelines. Geriatric specific!

Obesity, Osteoarthritis, Depression

Obesity. PCOS. CHF

Opioid addiction. Depression

Opioid addiction. Human trafficking (sex and slavery). Obesity

Opioid and chronic pain management - DEA. Fibromyalgia

Opioid crisis

Opioid use and abuse diversion. Alternative medications, care

Pain management

Palliative/pain management. Hospice care

Pediatric HTN management

Pediatric topics. Orthopedics. Dermatology

Peds and OB/Gyn

Post-op infections

Preventive medicine

Primary Care procedures (laceration repair). EKG, xray interpretation

Proper management of asthma. Depression treatment in Internal Medicine. Recent development in HIV management

Prostate cancer and PSA problems. HTN. Lipid. DM. Women's Health issues in Primary Care

Prostate cancer screening - totally uninformed. Dizziness. Fatigue - unexplained.

Depression. Incontinence

Psychology. Women's Health. Men's Health. Wholistic/supplement health (1)

Psychotherapies. Medication/application. Medication management for pain. Target opioids.

Obesity, the new epidemic

Pulmonary

PVD. Lymphedema

Rashes. Pneumonia. Dermatology. Chronic UTI's

Rheumatoid Arthritis, IBD, AAA, PVI

Rural

Shift work syndrome and sleep apnea

Skin rashes (Dermatology). Hormonal replacement therapy

Sleep apnea. Obesity. Evaluation of elevated LFTs/fatty liver/Rx. Evaluation of

Proteinuria/workup/Rx

Sports medicine

STD and bacterial infections. Pulmonary hypertension. PAD

Stroke

Stroke, COPD, Asthma

Surgical topics like breast, colon cancer

The new cure for Hep C - which patients are likely to be recommended for treatment

These topics covered were great

Thyroid diseases

Thyroid disorder. Chest pain

Thyroid disorders and management. Pancreatitis, management and alcoholism. Liver disorders

Topics addressing conflicts in Emergency Medicine

Topics on discussions of offering Palliative Care to patients and the diseases that would quality patients into Palliative Care programs. Managing CHF, COPD, CKD, Dementia

Treatment of AFib. Management of obesity. Management of back pain/pain management. Colon cancer screening

Treatment of gestational diabetes. Controlling hypertension in pregnant patient

Updated management in metabolic disease. HTN, Dyslipidemia, Diabetes. Also add thyroid problems

Vaginal prolapse. Immunizations - review. ECG

Workup for recurrent PE/DVT. Indications of MRI/CT scans in PCP office

Wound management, CPT using update, update on coding

Wound management; opioid deprescribing; preventative medicine/guidelines

Additional Comments

Always great presentations

awesome job everyone!

cannot view the video play on simucalst

COPD

cover ihss

Excellent

enjoyed the music played during audience polling!

excellant topics and speakers made them easily assimable

excellent

excellent

EXCELLENT ACTIVITY WILL LIKE TO SEE MORE SIMULCAST ACTIVITIES

Excellent Conference

Excellent conference, especially and including new to me Jan Basile, MD

Excellent home CME activities

excellent presentation

Excellent presentation and knowledgeable presenters

Excellent program

excellent program!!!

Excellent speakers, informative topics, and ability to participate on line

Excellent topics discussed today! Thank you

Excellent!! Loved this cost effective webinar and free CEUs!!

Excellent!!!

Excellent, knowledge, practical application to everyday tx. Interesting.

Exceptional discussion

For Dr. Rosenberg:

For Dr. Rosenberg: I was on Androgel for 11 years, s/p orchiectomy for Semenoma. My PSA was stable at 2.2 for those 11 years. My insurance company removed Androgel from their formulary. I was maintained on the dosage of 1/2 packet 6 days of the week and 1 full packet, 1 day of the week. My prescriptions have changed 3 times, based upon response, meaning testosterone level and maintenance. With each change, my PSA rose and continued to rise from initial 2.2 to 2.7, 3.2, 2.7, 4.6, 5.6. Further testing indicated a 12% risk. A biopsy was performed and all came back normal. I asked my Urologist to write a letter several times, to try to get approval for Androgel and relate the reason/justification for authorizing Androgel, based on 11 year history of stability on Androgel, vs the escalating PSA and higher dosage, to maintain testosterone level. My Urologist refused to submit a letter. His response was, "you will be considered 1 of 1". I could not believe his response. As a Clinician with prescriptive authority, who advocates for my patient and fight with insurance companies, for my patient, and could not believe my Urologist would not advocate based on sound data and a patient who is sound in mind and very rational and logical in approach. Your thoughts and comments please. Respectfully, Michael O. Mahler, CRNP, ANP-BC,

LCDR, USN, RET good CME Good info good presentation Good presentation Great **Great Conference** Great conference. Thank you great speakers and lecture were excellent **Great Staff** Great way to earn CME without the cost of travel I appreciate NACE for having this conference available I greatly appreciate opportunity to view conference from home and appreciate the opportunity to do so at no cost. I was not happy with Dr Rosnberg he approached the issue of PSA testing with a persistently negative attitude, everybody was wrong but him and I am not sure if anybody got any helpful info after all.except that if a 50y/o has a PSA over 1,5 be followed closely VS one who has less than 1,5 be checked every 5 years but I do not think this is the national reccomendation. I was planning on traveling from Indiana to this conference, had conflicting issues, and was so glad to see it was offered via live conference! Incorporate use of translator machines/staff with patient communications It was an excellent conference keep up the good work Long day but very worth it Love the live conference I could watch on the computer. Thanks!! loved the conference. Learned a lot Loved the convinience Ν n/a NA none None. Good course. nothing office i.v and billing online access was terrific! Please correct the date of my conference to 9/16/2017 prostate lecture extremely important really enjoyed the lectures Remote access to learning was a key point Stolar was an excellant speaker, very easy to understand, made a complicated topic very simple, thank you Thank you Thank you for a great series Thank you for all you do Thank you for continued learning opportunities online such as this Thank you for making this Conference available for those at a distance! However, the

speakers need to be aware of their time alottment when they are lecturing

Thank you for making this easily accessible

thank you for this service

Thank you very much . Appreciate your continuous efforts to keep us updated in medicine.

Thank you!

thank-you for bring great free CMEs to our homes- you are raising the bar of primary care thanks

Thanks for an Excellent CE program

thanks for providing this lecture for us.

Thanks for quite informative presentations

Thanks for the Presentations

Thanks for this CME opportunity.

Thanks so much.

Thanks.

The speaker shows up by simply clicking the link but seeing the slides requires the email address. Seems odd to disconnect the two. Thanks for your efforts! Very much appreciated!

this CME was on September 16, 2017. Not on the date on the top of the page

This does not appear to be the correct form for the webinar offered on 9/16/2017 (1)

this eval is different from today's lectures

THIS HAS BEEN A VERY WELL PRESENTED CONFERENCE!

THIS IS WRONG EVALUATION FOR NASHVILLE WEBINAR!

this web based experience was positive

Thought it was an excellent conference.

Truly wonderful conference--speakers were each excellent with their coverage of very pertinent topics and I so appreciated the opportunity to participate as remote audience member

Very educational.

Very good CME experience today!

Very good CMS course. thank you

Very good presentation

Very good! Thank you!

well done

Well done!

Χ